Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036302 | 0.88 | KMT2A (0.52) | KMT2AEPHX2ALDH1A1OPRD1FABP7 | |
| SCHEMBL525564 | 0.86 | KMT2A (0.59) | KMT2AEPHX2ITGB3ITGAVOPRD1 | |
| SCHEMBL30640436 | 0.86 | KMT2A (0.59) | KMT2AEPHX2ITGB3ITGAVOPRD1 | |
| SCHEMBL14485271 | 0.85 | KMT2A (0.59) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL31010055 | 0.85 | KMT2A (0.55) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL2057615 | 0.85 | KMT2A (0.55) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL3177417 | 0.85 | KMT2A (0.62) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL14485267 | 0.84 | KMT2A (0.57) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL2744319 | 0.84 | KMT2A (0.55) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL31652901 | 0.84 | KMT2A (0.56) | KMT2AEPHX2OPRD1FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896086-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | KMT2A 2223/4885EPHX2 675/4885MAPT 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.